ホーム>>Signaling Pathways>> MAPK Signaling>> RSK>>Pluripotin

Pluripotin (Synonyms: SC1)

カタログ番号GC17407

Pluripotin は、それぞれ 98 nM および 212 nM の KD を持つ ERK1 および RasGAP の二重阻害剤です。 Pluripotin は、RSK1、RSK2、RSK3、および RSK4 もそれぞれ 0.5、2.5、3.3、および 10.0 μM の IC50 で阻害します。

Products are for research use only. Not for human use. We do not sell to patients.

Pluripotin 化学構造

Cas No.: 839707-37-8

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$108.00
在庫あり
2mg
$59.00
在庫あり
5mg
$89.00
在庫あり
10mg
$158.00
在庫あり
25mg
$315.00
在庫あり
50mg
$558.00
在庫あり
100mg
$720.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Pluripotin is a dual inhibitor of ERK1 and RasGAP with KDs of 98 nM and 212 nM, respectively. Pluripotin also inhibits RSK1, RSK2, RSK3, and RSK4 with IC50s of 0.5, 2.5, 3.3, and 10.0 µM, respectively.

Pluripotin (SC-1) inhibits Abl1, p70S6K, PLK2, RSK1, RSK2, RSK3, RSK4 with IC50s of 0.005, 1.4, 2.2, 0.5, 2.5, 3.3, 10.0 µM,respectively. Pluripotin (SC-1) decreases cell growth for 7 colon tumor cell lines. After a five day exposure to 0.1 µM SC-1, the seven colon tumor lines are evaluated for changes in cell number and viability. There is a statistically significant decrease in cell number but >95% viability[2].

References:
[1]. Chen S, et al. Self-renewal of embryonic stem cells by a small molecule. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17266-71.
[2]. Mertins SD, et al. A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept. PLoS One. 2013;8(2):e57099.

レビュー

Review for Pluripotin

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pluripotin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.